Department of Pathology, Mahatma Gandhi Institute of Medical Sciences, Sevagram, Maharashtra, India.
PLoS One. 2009 Dec 4;4(12):e8180. doi: 10.1371/journal.pone.0008180.
Breast cancer is the most common malignancy affecting females worldwide but conventional risk factors are able to explain only a small proportion of these cases. A possible viral etiology for breast cancer has been proposed and Epstein-Barr Virus (EBV) is a widely researched candidate virus. The aim of the present study, first one of its kind from India, was to determine if there is a greater association of EBV infection with breast cancer patients as compared to patients with benign breast diseases.
We looked for expression of Epstein-Barr Virus Nuclear Antigen-1 (EBNA-1) in breast cancer tissue specimens by employing immunohistochemistry (IHC). We also measured levels of anti-EBNA-1 Immunoglobulin (IgG) antibodies in stored sera of these patients using commercial Enzyme linked Immunosorbent Assay (ELISA) kit. Patients with benign breast diseases were used as a comparison group for both immunohistochemical and serological analysis.
58 cases of malignant breast disease and 63 of benign breast disease (controls) were included in the study. Using manufacturer determined cut-off of 3 IU/ml, 50/55 tested (90.9%) cases and 27/33 tested (81.8%) controls were seropositive for anti-EBNA-1 IgG. Mean antibody levels were significantly higher for cases (54.22 IU/ml) as compared to controls (18.68 IU/ml). IHC for EBNA-1 was positive in 28/51 cases (54.9%). No IHC positivity was noted in the tested 30 controls. Our results show that EBNA-1 expression is seen in a significant proportion of breast cancer tissue specimens from rural India and as compared to patients with benign breast diseases these patients also have a higher immunological response against EBNA-1.
乳腺癌是全球女性中最常见的恶性肿瘤,但传统的危险因素只能解释其中的一小部分病例。已经提出了乳腺癌的一种可能的病毒病因,EB 病毒(EBV)是一种广泛研究的候选病毒。本研究旨在确定 EBV 感染与乳腺癌患者的关联是否大于良性乳腺疾病患者,这在印度尚属首例。
我们通过免疫组织化学(IHC)检测乳腺癌组织标本中 EBV 核抗原-1(EBNA-1)的表达。我们还使用商业酶联免疫吸附试验(ELISA)试剂盒测量这些患者储存血清中的抗 EBNA-1 免疫球蛋白(IgG)抗体水平。良性乳腺疾病患者用作免疫组织化学和血清学分析的比较组。
研究纳入了 58 例恶性乳腺疾病和 63 例良性乳腺疾病(对照组)患者。使用制造商确定的 3 IU/ml 截断值,55 例中有 50 例(90.9%)和 33 例中有 27 例(81.8%)检测到抗 EBNA-1 IgG 阳性。病例组的平均抗体水平明显高于对照组(54.22 IU/ml 对 18.68 IU/ml)。EBNA-1 的 IHC 阳性率为 51 例中的 28 例(54.9%)。在测试的 30 例对照中未观察到 IHC 阳性。我们的结果表明,EBNA-1 表达在印度农村的乳腺癌组织标本中占很大比例,与良性乳腺疾病患者相比,这些患者对 EBNA-1 的免疫反应也更高。